Brief: Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
03/01/2024 12:19
Jan 3 (Reuters) - Tango Therapeutics Inc TNGX.O :
* TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE
1/2
TRIAL OF TNG348 IN PATIENTS WITH BRCA1/2-MUTANT AND OTHER HRD+
CANCERS
Source text for Eikon: ID:nGNX8qfb31
Further company coverage: TNGX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,